Lupin 2024

Glenmark receives ANDA approval for arformoterol tartrate inhalation solution

Print Friendly, PDF & Email

MUMBAI, India Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for arformoterol tartrate inhalation solution, 15 mcg/2 mL, Unit-Dose Vials, the generic version of Brovana Inhalation Solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals.

Arformoterol tartrate inhalation solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, N.C., and marks the company’s first nebulizer approval.


ECRM_06-01-22


Comments are closed.

Centrum 7/6  banner